Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2021

Waitkus Matthew S, Yan Hai

Abstract excerpt

Isocitrate dehydrogenase (IDH) active-site mutations cause a neomorphic enzyme activity that results in the formation of supraphysiologic concentrations of D-2-hydroxyglutarate (D-2HG). D-2HG is thought to be an oncometabolite that drives the formation of cancers in a variety of tissue types by altering the epigenetic state of progenitor cells by inhibiting enzymes involved in histone and DNA demethylation. This...

Topics

Join the communities discussing this publication.

Brain Neoplasms
Clinical Trials as Topic
DNA Methylation
Enzyme Inhibitors
Epigenesis, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Isocitrate Dehydrogenase

Source

Identifiers

PMID: 32883741
DOI: 10.1158/1078-0432.CCR-20-1827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.PMID 32883741Read ↗

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.Semantic proximity Read ↗

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.Semantic proximity Read ↗

Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.Semantic proximity Read ↗

IDH mutations in cancer and progress toward development of targeted therapeutics.Semantic proximity Read ↗

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-MutationsSemantic proximity Read ↗

Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic StrategiesSemantic proximity Read ↗

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesSemantic proximity Read ↗

IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?Semantic proximity Read ↗

The implications of IDH mutations for cancer development and therapy.Semantic proximity Read ↗

Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models.Semantic proximity Read ↗

Biological Role and Therapeutic Potential of IDH Mutations in Cancer.Semantic proximity Read ↗

Metabolic consequences of oncogenic IDH mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.